the access record, read straight
MOTS-c Legal Status, FDA 503A Category, and Compounding Access
Access is under active FDA review and may expand in 2026 — anchored on a single published fact: MOTS-c is individually named on the FDA's July 23-24, 2026 advisory-committee agenda as a substance being considered for the 503A bulks list.
In plain English
The short version of MOTS-c legal status: in the United States, MOTS-c is a research peptide, not an FDA-approved medicine, and you cannot buy it over the counter as a drug or supplement. But the picture has momentum. The FDA has scheduled MOTS-c for a public advisory-committee discussion in July 2026 about whether it could become eligible for pharmacy compounding. That is a scheduled conversation — a step in evaluation — not a decision, and nothing about its status has changed yet. Below we explain the rules, the agenda item, and how legally compounded peptide access works in general terms. This is general information, not medical or legal advice, and not an offer to sell or supply anything.
The current fact
MOTS-c — a 16-amino-acid mitochondrial-derived peptide encoded within the mitochondrial 12S rRNA region — is a research peptide and is not an FDA-approved drug for any indication [1][17].
Under the U.S. Federal Food, Drug, and Cosmetic Act, a bulk drug substance may be used in 503A pharmacy compounding only if it has an applicable USP/NF monograph, is a component of an FDA-approved drug, or appears on FDA's 503A bulks list [17]. Substances not yet on that list are evaluated by FDA through a public nomination process, informed by the Pharmacy Compounding Advisory Committee (PCAC) [17]. MOTS-c is one of the bulk drug substances FDA has scheduled for PCAC evaluation [19]. Being under evaluation is not the same as being on the bulks list or approved for compounding.
The 503A and 503B framework
Drug compounding in the U.S. is governed by two sections of the Act [17]. Section 503A covers traditional, patient-specific compounding by state-licensed pharmacies, federal facilities, and licensed physicians — generally made to fill a valid prescription for an individual patient. Section 503B covers registered "outsourcing facilities" that may compound larger batches under cGMP-style oversight and FDA registration and inspection [17].
The ingredient question is the gating one. A compounder may use a bulk drug substance — an active pharmaceutical ingredient used as a starting material, rather than a finished approved drug — only when that substance has an applicable USP/NF monograph, is a component of an FDA-approved drug, or is on the relevant FDA bulks list [17]. Anything else must go through nomination and FDA evaluation, with PCAC input, before it could be eligible [17]. Importantly, FDA approval of a finished drug is a separate question from whether a bulk substance may be used in compounding; MOTS-c is neither an approved drug nor on the bulks list [17][19].
What is actually scheduled in 2026
Here is the momentum, stated precisely. MOTS-c is individually named on the published agenda of the FDA Pharmacy Compounding Advisory Committee meeting scheduled for July 23-24, 2026, as a bulk drug substance "being considered for inclusion on the 503A Bulks List" — evaluated in both its free base and acetate forms [19]. The same agenda also lists BPC-157, TB-500, and KPV [19].
That is a scheduled evaluation and discussion only. It is not a listing decision, not a reclassification, and not a change in MOTS-c's current status [19]. A PCAC discussion is advisory; it does not bind FDA, and no outcome should be assumed or dated [19]. MOTS-c's present-tense status remains: a research peptide, not FDA-approved, scheduled for PCAC evaluation. The audited reference assigns MOTS-c no numbered 503A category, and neither do we — its standing is exactly what is described here, not a borrowed classification from any other substance.
A note on what we will not claim
Because the internet is full of confident regulatory claims that have not happened, this site states what is verifiable and nothing more. We do not assert any reclassification of peptides as already done, dated, or certain. Reports circulating in early 2026 — including an attributed statement that roughly 14 of the peptides placed in a higher-risk category in 2023 would move back, and vendor claims that specific peptides were "removed" in April 2026 — could not be confirmed from an authoritative FDA source and are explicitly treated here as unconfirmed reports of pending matters, not facts [17][19]. The only forward-looking item we anchor on is the published, scheduled July 2026 PCAC agenda, framed strictly as a scheduled discussion [19].
How legally compounded peptide access works
In general terms, a legally compounded medication is prepared only after a defined pathway [18]. First, a patient is evaluated by an appropriately licensed prescriber — in person or through a compliant telehealth encounter — who determines whether a compounded preparation is clinically appropriate [18]. Telehealth here is a front-end channel to that consultation; it does not change which substances are eligible to be compounded, and it does not remove the need for a legitimate prescriber-patient relationship and a valid prescription [18].
If appropriate and lawful, the prescriber issues a valid, patient-specific prescription, which is then dispensed by a state-licensed 503A compounding pharmacy or, for office or batch use, sourced from an FDA-registered 503B outsourcing facility [18]. The compounder may use the requested active ingredient only if that ingredient is eligible under the 503A/503B bulk-substance rules; an ingredient FDA has flagged for significant safety risks is not eligible for routine 503A compounding while that status stands [18]. This is a description of the regulatory landscape, not medical or legal advice, and not an offer to sell or supply MOTS-c or any substance [18].
MOTS-c access, in three direct answers
Is MOTS-c legal?
MOTS-c is a research peptide and is not an FDA-approved drug for any indication; it is sold only as a research chemical for laboratory use, with no approved human indication, formulation, or dosing [1][17]. It is individually named on the FDA's July 2026 PCAC agenda as a substance under evaluation for the 503A bulks list — a scheduled discussion, not a change in status [19].
Can you get MOTS-c from a compounding pharmacy?
Not as a matter of routine. A 503A pharmacy may use a bulk substance only if it has a USP/NF monograph, is a component of an approved drug, or is on FDA's 503A bulks list [17]. MOTS-c is none of these; it is under PCAC evaluation, not on the list [17][19]. Any lawful compounded access also requires a licensed-prescriber evaluation and a valid, patient-specific prescription [18].
What is the FDA 503A status of MOTS-c?
MOTS-c is not on FDA's 503A bulks list and is not an FDA-approved drug; it is a bulk drug substance scheduled for evaluation by the Pharmacy Compounding Advisory Committee at the July 23-24, 2026 meeting [17][19]. The audited reference assigns MOTS-c no numbered 503A category, so none is stated here; its status is "scheduled for PCAC evaluation" [19].